Print（PDF/115KB） Nov. 02, 2018 R&D

Sumitomo Dainippon Pharma announces the Clinical Data of Investigational Anti-Cancer Agent Alvocidib will be presented at ASH 2018

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that the clinical data for an investigational inhibitor of cyclin-dependent kinase 9 (CDK9), alvocidib (generic name), will be presented in an oral session at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from December 1 to 4, 2018.

For your information, the clinical data to be presented at the oral session are the stage-1 results of a phase 2 study, Zella 201, for alvocidib in patients with relapsed or refractory MCL-1-dependent Acute Myeloid Leukemia (NCT02520011).

The abstract is now available on the official website of ASH.
（https://ash.confex.com/ash/2018/webprogram/start.html）

Outline of oral presentation at the ASH 2018

Abstract number	Title of oral presentation	Date and Time, Location	Study number	Cancer Type
#30	Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)	December 1, 2018 8：45 AM- (local time), Seaport Ballroom F	Zella 201（NCT02520011）	AML

(Reference)

【About inhibitor of cyclin-dependent kinase 9 (CDK9) alvocidib】

Alvocidib is a small molecule inhibitor of cyclin-dependent kinase 9 (CDK9), a member of cyclin-dependent kinase family, which activates transcription of cancer-related genes. The subsequent down-regulation of MCL-1, an anti-apoptotic gene, may be responsible for the potential clinical anti-cancer activity observed with alvocidib.

【About MCL-1(Myeloid Cell Leukemia 1)】

MCL-1 is an anti-apoptotic factor.